Merge Labs explores advanced brain–computer interface technologies that combine ultrasound-based neural interfacing with gene therapy approaches. The company’s work focuses on achieving high-bandwidth, non-invasive interaction with the brain by enhancing neural sensitivity to ultrasound stimulation and sensing. Its platform is positioned at the intersection of neurotechnology, biotechnology, and artificial intelligence. Merge Labs operates within experimental and early-stage research contexts.

The technology concept leverages ultrasound as a modality for interacting with neural tissue at depth without implanted electronics. Gene therapy techniques are explored to modify neural responsiveness, potentially enabling more precise and efficient coupling between ultrasound signals and neural activity. This combined approach is intended to support both neural sensing and modulation with higher bandwidth than conventional non-invasive methods. The platform emphasizes exploratory research into new mechanisms for scalable brain–machine interaction.

Merge Labs targets long-term applications related to human–AI integration and advanced neural interfacing. The work is intended for investigational and preclinical research rather than near-term clinical or consumer deployment. Its positioning reflects broader interest in hybrid biological and physical approaches to overcoming current limits of non-invasive brain–computer interfaces.